Diagnostic roles of proliferative markers in pathological Grade of T1 Urothelial Bladder Cancer.
Ki-67
mitotic index
telomerase reverse transcriptase promoter mutations
urothelial bladder cancer
Journal
Journal of Cancer
ISSN: 1837-9664
Titre abrégé: J Cancer
Pays: Australia
ID NLM: 101535920
Informations de publication
Date de publication:
2021
2021
Historique:
received:
24
08
2020
accepted:
14
02
2021
entrez:
15
4
2021
pubmed:
16
4
2021
medline:
16
4
2021
Statut:
epublish
Résumé
The stage T1 urothelial bladder cancer (T1 UBC) tumor grade classification is important for prognosis and clinical management. However, the reproducibility of this two-grade classification system is limited in regards to pathological diagnosis, and there is lack of ideal, objective and easily detected markers for pathological diagnosis. In our study, bladder urothelial lesions from a total of 124 patients diagnosed pathologically after transurethral resection of the bladder tumor (TURBT) were collected, including non-cancerous lesions from 33 patients and lesions from 91 T1 UBC patients. A series of previous studies have suggested some common and valuable factors in the diagnosis and prognosis of UBC, but there are still some controversial factors, such as the mitotic figure (MF) of tumor cell, cell proliferation index Ki-67, graded differentiation marker CK20, P53, P504S and carcinogenesis associated telomerase reverse transcriptase (TERT) promoter mutations. The purpose of this study was to evaluate the value of these factors in the pathological grading diagnosis of T1 UBC. The results showed that gender, lesion size, mitotic index (MI), CK20, P53, Ki-67, P504S and TERT promoter hot spot mutations (C228T and C250T) were correlated with T1 UBC diagnosis (P<0.05). The MI, Ki-67 and P504S were correlated with the pathological grade of T1 UBC (P<0.05). Logistic regression analysis showed that the MI and Ki-67 were independent risk factors for high-grade (HG) of T1 UBC (P<0.05). The combined detection of the MI, Ki-67 and P504S in a multivariate diagnostic model improved the diagnostic accuracy of assigning the T1 UBC pathological grade (AUC=0.904, 95%CI: 0.824~0.956, P<0.05). In conclusion, MI and Ki-67, as important markers of histopathology and cell proliferation, can be easily measured and have good reproducibility. These markers may be meaningful parameters for assigning the pathological grade of UBC.
Identifiants
pubmed: 33854611
doi: 10.7150/jca.52336
pii: jcav12p2498
pmc: PMC8040703
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2498-2506Informations de copyright
© The author(s).
Déclaration de conflit d'intérêts
Competing Interests: The authors have declared that no competing interest exists.
Références
Eur Urol. 2017 Nov;72(5):801-813
pubmed: 28457661
J Natl Compr Canc Netw. 2020 Mar;18(3):329-354
pubmed: 32135513
Urol Oncol. 2010 Jul-Aug;28(4):409-28
pubmed: 20610279
J Biomed Biotechnol. 2012;2012:891961
pubmed: 22919278
Mod Pathol. 2001 Apr;14(4):267-72
pubmed: 11301341
Br J Cancer. 2007 Jun 4;96(11):1711-5
pubmed: 17505513
J Cancer Res Clin Oncol. 1992;118(8):615-20
pubmed: 1517282
Int J Cancer. 1992 May 28;51(3):396-403
pubmed: 1592531
Oncotarget. 2017 Oct 13;8(59):100614-100630
pubmed: 29246006
Eur Urol. 2019 Nov;76(5):639-657
pubmed: 31443960
Clin Genitourin Cancer. 2013 Dec;11(4):537-44
pubmed: 23850551
J Urol. 2017 Oct;198(4):824-831
pubmed: 28433642
Histopathology. 1995 Aug;27(2):169-74
pubmed: 8835265
Am J Surg Pathol. 1998 Dec;22(12):1435-48
pubmed: 9850170
Curr Opin Urol. 2009 Sep;19(5):516-21
pubmed: 19553819
Ann Diagn Pathol. 2016 Apr;21:7-11
pubmed: 27040924
Gut. 1995 Jun;36(6):848-52
pubmed: 7615272
Virchows Arch. 2006 Mar;448(3):325-30
pubmed: 16315020
Virchows Arch. 2008 Aug;453(2):165-70
pubmed: 18648853
Eur Urol. 2014 Feb;65(2):370-1
pubmed: 24184027
Eur Urol. 2009 Sep;56(3):430-42
pubmed: 19576682
Protein Cell. 2010 Jan;1(1):22-32
pubmed: 21203995
Nature. 2014 Mar 20;507(7492):315-22
pubmed: 24476821
Cancer Res. 2000 Dec 15;60(24):6788-93
pubmed: 11156366
Int J Oncol. 1992 Aug;1(3):387-92
pubmed: 21584558
Lancet. 1999 Mar 20;353(9157):974-7
pubmed: 10459907
Eur Urol. 2014 Jan;65(1):218-26
pubmed: 22633802
J Lipid Res. 2000 Nov;41(11):1890-6
pubmed: 11060359
Anal Quant Cytopathol Histpathol. 2016 Feb;38(1):23-30
pubmed: 27363063
Mod Pathol. 2000 Dec;13(12):1315-23
pubmed: 11144928
Cancer Commun (Lond). 2019 Apr 29;39(1):22
pubmed: 31030667
Am J Pathol. 2002 Sep;161(3):841-8
pubmed: 12213712
J Urol. 2003 Jan;169(1):96-100; discussion 100
pubmed: 12478112
Eur J Histochem. 2020 Mar 26;64(2):
pubmed: 32214283
Int J Cancer. 2015 Oct 1;137(7):1621-9
pubmed: 25809917